Labiotech tracks macrocyclic drug momentum in cardiometabolic disease
The trade feature surveys how macrocyclic chemistry, including peptide macrocycles, is being applied to metabolic and cardiovascular targets.
TR
By Tom Reyes · Markets Editor
Sep 30 09:02 ETSource: labiotech.eu
The wire
- 01Labiotech reviews rising industry interest in macrocyclic drugs aimed at cardiometabolic indications.
- 02Macrocyclic and oral peptide formats are a growing route to drug targets that conventional small molecules struggle to reach, relevant to anyone tracking the peptide pipeline.
- 03The piece is an overview rather than a company event or data readout; specifics on programs and timelines are not detailed here.
From the source
Read at labiotech.euHow macrocyclic drugs are gaining momentum in the cardiometabolic disease space
